11:06 AM EST - NetraMark Holdings Inc. : Announced a strategic research collaboration with Fondazione per la Medicina Personalizzata (FMP) to analyze its landmark ROME Phase II oncology trial dataset (NCT04591431) using NetraMark’s proprietary NetraAI platform, with the objective of identifying clinically actionable insights that may inform future precision-oncology strategies and clinical trial design. NetraMark Holdings Inc.
shares T.AIAI are trading unchanged at $0.93.
